Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ELVN
stocks logo

ELVN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.370
-19.57%
--
--
-0.455
-20.18%
--
--
-0.500
+2.04%
Estimates Revision
The market is revising No Change the revenue expectations for Enliven Therapeutics, Inc. (ELVN) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 6.20%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-11.77%
In Past 3 Month
Stock Price
Go Up
up Image
+6.20%
In Past 3 Month
Wall Street analysts forecast ELVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELVN is 41.00 USD with a low forecast of 36.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast ELVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELVN is 41.00 USD with a low forecast of 36.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 21.400
sliders
Low
36.00
Averages
41.00
High
48.00
Current: 21.400
sliders
Low
36.00
Averages
41.00
High
48.00
H.C. Wainwright
H.C. Wainwright
NULL -> Buy
maintain
$40 -> $48
2025-07-02
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$40 -> $48
2025-07-02
maintain
NULL -> Buy
Reason
H.C. Wainwright raised the firm's price target on Enliven to $48 from $40 and keeps a Buy rating on the shares after the company presented updated results from the Phase 1a/1b ENABLE trial at EHA 2025. Following the presentation at the medical meeting, the firm contends that ELVN-001 could become "the go-to agent" in chronic myelogenous leukemia.
Goldman Sachs
Salveen Richter
NULL -> Buy
upgrade
$37
2025-06-17
Reason
Goldman Sachs
Salveen Richter
Price Target
$37
2025-06-17
upgrade
NULL -> Buy
Reason
Goldman Sachs analyst Salveen Richter assigned of Enliven with a Buy rating and $37 price target from a previous Early-Stage Biotech designation. The firm cites the company's continued positive Phase 1 data and the announcement of a planned Phase 3 initiation in 2026 for tyrosine kinase inhibitor ELVN-001 in chronic myeloid leukemia for the Buy rating. ELVN-001 remains well-tolerated, with no increased cardiovascular toxicity, and the data supports the potential for once daily dosing without the need for fasting and low drug-drug interactions, the analyst tells investors in a research note.
Baird
Colleen Kusy
Outperform
maintain
$40 -> $52
2025-06-17
Reason
Baird
Colleen Kusy
Price Target
$40 -> $52
2025-06-17
maintain
Outperform
Reason
Baird analyst Colleen Kusy raised the firm's price target on Enliven to $52 from $40 and keeps an Outperform rating on the shares. The firm updated its model as its ELVN-001 data continues to show improvement which supports its compelling profile.
JonesResearch
Soumit Roy
Buy
downgrade
$36 -> $27
2025-05-16
Reason
JonesResearch
Soumit Roy
Price Target
$36 -> $27
2025-05-16
downgrade
Buy
Reason
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$39 -> $40
2025-05-15
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$39 -> $40
2025-05-15
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Enliven to $40 from $39 and keeps a Buy rating on the shares following the Q1 report.
HC Wainwright & Co.
Robert Burns
Strong Buy
Maintains
$37 → $39
2025-03-21
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$37 → $39
2025-03-21
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Enliven Therapeutics Inc (ELVN.O) is -12.21, compared to its 5-year average forward P/E of -9.27. For a more detailed relative valuation and DCF analysis to assess Enliven Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-9.27
Current PE
-12.21
Overvalued PE
-7.14
Undervalued PE
-11.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.67
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-2.26
Undervalued EV/EBITDA
-7.09

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
92593.48
Current PS
0.00
Overvalued PS
193905.42
Undervalued PS
-8718.46
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

ELVN News & Events

Events Timeline

(ET)
2025-11-12
16:12:57
Enliven announces Q3 EPS of 32 cents, compared to a loss of 48 cents last year.
select
2025-10-17 (ET)
2025-10-17
13:08:15
Clear Street: Enliven and Novartis Medications Set to Dominate CML Market
select
2025-08-13 (ET)
2025-08-13
16:09:51
Enliven reports Q2 EPS (49c) vs. (41c) last year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
11-13NASDAQ.COM
ELVN Surpasses Important Moving Average Threshold
  • 52 Week Range: ELVN's stock has a 52-week low of $13.30 and a high of $27.59, with the last trade recorded at $20.30.
  • Market Analysis: The article suggests checking other stocks that have recently crossed above their 200-day moving average.
  • Author's Perspective: The views expressed in the article are solely those of the author and do not necessarily represent Nasdaq, Inc.
  • Stock Performance Insight: The information highlights the volatility and performance range of ELVN's stock over the past year.
[object Object]
Preview
9.5
11-13PRnewswire
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update

  • Trial Progress: Enliven Therapeutics has completed the Phase 1b portion of the ENABLE trial for ELVN-001, a treatment for chronic myeloid leukemia (CML), and is on track to initiate a Phase 3 pivotal trial in 2026.

  • Financial Position: The company reported a strong financial position with $478 million in cash and equivalents, expected to fund operations into the first half of 2029, alongside a net loss of $20.1 million for Q3 2025.

  • Pipeline Updates: ELVN-001 is a selective small molecule kinase inhibitor targeting the BCR::ABL gene fusion, with ongoing presentations of trial data at various medical conferences, highlighting its potential effectiveness.

  • Upcoming Events: Enliven will present additional data from the ENABLE trial at the ASH 2025 Annual Meeting and participate in the Jefferies Global Healthcare Conference, showcasing their commitment to advancing CML treatment options.

[object Object]
Preview
4.0
09-09NASDAQ.COM
Enliven Therapeutics, Inc. (ELVN) Receives Upgrade to Buy: Key Information You Need to Know

  • Zacks Rank Upgrade: Enliven Therapeutics, Inc. (ELVN) has been upgraded to a Zacks Rank #2 (Buy) due to a positive trend in earnings estimates, indicating potential stock price increases.

  • Earnings Estimate Revisions: The Zacks rating system, which correlates earnings estimate revisions with stock movements, suggests that the recent upgrades reflect an improvement in the company's business outlook, making it a strong candidate for market-beating returns.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Enliven Therapeutics Inc (ELVN) stock price today?

The current price of ELVN is 21.4 USD — it has increased 1.9 % in the last trading day.

arrow icon

What is Enliven Therapeutics Inc (ELVN)'s business?

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.

arrow icon

What is the price predicton of ELVN Stock?

Wall Street analysts forecast ELVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELVN is 41.00 USD with a low forecast of 36.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Enliven Therapeutics Inc (ELVN)'s revenue for the last quarter?

Enliven Therapeutics Inc revenue for the last quarter amounts to -25.10M USD, decreased -7.29 % YoY.

arrow icon

What is Enliven Therapeutics Inc (ELVN)'s earnings per share (EPS) for the last quarter?

Enliven Therapeutics Inc. EPS for the last quarter amounts to -13279000.00 USD, increased 8.71 % YoY.

arrow icon

What changes have occurred in the market's expectations for Enliven Therapeutics Inc (ELVN)'s fundamentals?

The market is revising No Change the revenue expectations for Enliven Therapeutics, Inc. (ELVN) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 6.20%.
arrow icon

How many employees does Enliven Therapeutics Inc (ELVN). have?

Enliven Therapeutics Inc (ELVN) has 62 emplpoyees as of December 05 2025.

arrow icon

What is Enliven Therapeutics Inc (ELVN) market cap?

Today ELVN has the market capitalization of 1.27B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free